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OBJECTIVE — The purpose of this study was to test the hypothesis that bezaﬁbrate, an
approved ﬁbrate, can prevent or delay type 2 diabetes.
RESEARCH DESIGN AND METHODS — This was a retrospective cohort study using
data from routine medical practice in the U.K., as captured by the General Practice Research
Database (GPRD). Individuals chronically exposed to bezaﬁbrate were compared with individ-
uals chronically exposed to other ﬁbrates. Hazard ratios (HRs) for incident type 2 diabetes were
calculatedusingaCoxproportionalhazardsmodel.Aposthocanalysiswasusedtoexaminethe
effect of bezaﬁbrate on progression to use of oral antidiabetic medications or insulin in individ-
uals with diabetes at baseline.
RESULTS — Bezaﬁbrate users had a lower hazard for incident diabetes than users of other
ﬁbrates (HR 0.66 [95% CI 0.53–0.81]). This effect became stronger with increasing duration of
therapy. Post hoc analysis of the effect of bezaﬁbrate on progression of preexisting diabetes also
showed a lower hazard for progression to use of antidiabetic medication (0.54 [0.38–0.76]) or
progression to use of insulin (0.78 [0.55–1.10]).
CONCLUSIONS — Bezaﬁbrate appears to have clinically important antidiabetic properties.
Randomized controlled trials should be considered to assess the utility of bezaﬁbrate in treating
patients with diabetes or in preventing diabetes in high-risk patients.
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T
ype 2 diabetes is a major public
health threat, expected to affect
more than 221 million people
worldwide by 2010 (1). One key target
for diabetes drug development is the per-
oxisome proliferator–activated receptor
(PPAR) (2,3). There are three isotypes
that are of speciﬁc interest in metabolic
diseases: PPAR-, PPAR-, and PPAR-.
The thiazolidinediones (e.g., pioglita-
zone) are PPAR- agonists used to treat
diabetes through improvement of insulin
response. The ﬁbrates are PPAR- ago-
nists used to treat dyslipidemia by raising
HDL and lowering triglycerides. PPAR-
remains an investigational drug target
with potential uses in diabetes, dyslipide-
mia, and obesity (4). Because dyslipidemia
and diabetes are commonly comorbid, at-
tempts have been made to create dual




agents, at least one observer has pointed
outthattheﬁbratebezaﬁbrateactuallyisa
pan-PPAR agonist and affects insulin re-
sistance(5).Posthocanalysesofaplacebo-
controlled randomized trial showed that
bezaﬁbrate may postpone or prevent type
2 diabetes (5,6). During a mean 6 years of
follow-up,hazardratios(HRs)versuspla-
cebo for incident diabetes were 0.59
(95%CI0.39–0.91)inobesepatients(5)
and 0.70 (95% CI 0.49–0.99) in pre-
diabetic patients (6). These clinical end
point data were supported by biochemi-
cal evidence showing that bezaﬁbrate
slowed progression of insulin resistance
(7).
Studies of the other ﬁbrates (gemﬁ-
brozil, fenoﬁbrate, ciproﬁbrate, and cloﬁ-
brate) have not shown such effects
(8–14), and these drugs are far more se-
lective for PPAR- than bezaﬁbrate (15).
Hence,itisreasonabletohypothesizethat
the status of bezaﬁbrate as a pan-PPAR
agonistmaygiveitantidiabeticproperties
unique among ﬁbrates.
Although not approved in the U.S.,
bezaﬁbratehasbeenwidelyprescribedfor
dyslipidemia in the U.K. We used obser-
vational data to examine the a priori hy-
pothesis that bezaﬁbrate is unique among




Database (GPRD). Personal information
was removed before inclusion in the da-
tabase. The requirement for informed
consent was waived by the University of




The GPRD contains data abstracted from
a computerized medical record system
usedbyasubsetofgeneralpracticesinthe
U.K. Ninety-eight percent of the U.K.
population receives all forms of health
care through their general practitioners.
The database is broadly representative of
the U.K. population in terms of sex, age,
and geography (16). We used data from
1988 through 2002.
The information prospectively col-
lected in the database includes demo-
graphic information, all prescriptions
written by the general practitioner, clini-
cal diagnoses, specialty consultation
notes, and hospital discharge diagnoses.
Medical diagnoses are classiﬁed using
Read Clinical Classiﬁcation and the Ox-
ford Medical Information System codes.
Participating general practices follow
prospectively designed protocols for re-





2Centocor Research and Development, Malvern, Pennsylvania, and Pre-
ventive Cardiovascular Medicine and Lipid Clinic, Department of Medicine, University of Pennsylvania
Health System, Philadelphia, Pennsylvania.
Corresponding author: James Flory, jﬂory@mail.med.upenn.edu.
Received 2 October and accepted 4 January 2009.
Published ahead of print at http://care.diabetesjournals.org on 8 January 2009. DOI: 10.2337/dc08-1809.
No sponsor had any role in the design and conduct of the study; collection, management, analysis, and
interpretation of the data; and preparation, review, or approval of the manuscript.
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Clinical Care/Education/Nutrition/Psychosocial Research
ORIGINAL ARTICLE
DIABETES CARE, VOLUME 32, NUMBER 4, APRIL 2009 547tion and uploading it to the research
database. Data reaching predeﬁned qual-
itystandardsaresodesignated.Morethan
400 published epidemiological studies
have been performed using the GPRD
(16,17).
Study cohort
From all patients being followed in the
GPRD, we included only person-time
from individuals who were exposed to a
ﬁbrate. Individuals were only included
who had been registered and up-to-
standard with the GPRD for at least 12
months before initiation of the exposure
drug, making this an inception cohort.
Because the primary outcome of in-
terest was incident diabetes, any diagnos-
tic code for diabetes or any use of home
glucose-monitoring equipment or of
drugs that are only used to treat diabetes
(insulin, biguanides, sulfonylureas, thia-
zolidinediones, or acarbose) before the
ﬁrstﬁbrateprescriptionorwithintheﬁrst
90 days of ﬁbrate therapy excluded that
individual from participation in the pri-
mary analysis. The rationale for this ex-
clusion was to avoid including prevalent
diabetic subjects in the study cohort.
Exposure deﬁnition
The study group included those with
more than one prescription for bezaﬁ-
brate, as a way to identify those receiving
chronic treatment. Because we excluded
individuals developing diabetes within
the ﬁrst 90 days of therapy, we began fol-
low-up with the 91st day of ﬁbrate ther-
apy. The duration of each prescription
was either provided in the database or,
when this information was missing, esti-
mated from the number of pills dis-
pensed. Exposure was assumed to
continue 30 days after the end of the ex-
pected duration of the last prescription.
Gaps over 60 days longer than expected
betweenprescriptionswereconsideredto
mark a last prescription, although a pa-
tient could reenter the cohort with the
next prescription. Clustering methods
were used to account for single patients
contributing multiple blocks of time to
the cohort, and sensitivity analysis was
done in which patients were censored at
theﬁrstgapandnotallowedtoreenterthe
cohort.
Control groups were deﬁned using
parallelcriteria,withperson-timeforcon-
trol subjects deﬁned by exposure to other
ﬁbrates without any history of bezaﬁbrate
use. The prespeciﬁed plan for this study
wastomaximizepowerbyconsideringall
nonbezaﬁbrate ﬁbrates as a single expo-
sure and only distinguishing between in-
dividual ﬁbrates in a secondary analysis.
Any patient who switched from one
study group to another was censored at
the time of the switch. In a secondary
analysis, each speciﬁc ﬁbrate constituted
its own exposure group, compared with
bezaﬁbrate.
Outcome deﬁnition
The outcome of interest was clinical diag-
nosis of or treatment for diabetes, deﬁned
by at least two codes indicative of diabe-
tes. Such codes included any diagnostic
code for diabetes, any prescription for
home glucose-monitoring equipment, or
any prescription for insulin or an oral an-
tidiabetic drug.
Post hoc analysis
In a post hoc analysis, two additional co-
horts were created. These consisted of in-
dividuals who would have been eligible
for the primary study but were excluded
because of diabetes occurring before the
91st day of ﬁbrate treatment. These indi-
viduals with baseline diabetes were di-
vided into two groups. The new cohort
consisted of individuals who had un-
treated diabetes at baseline (as identiﬁed
by medical codes for diabetes or use of
home glucose-monitoring equipment but
no use of any antidiabetic medication).
For this cohort, the outcome of interest
was progression to use of any antidiabetic
medication. In addition, individuals who
were using oral antidiabetic therapy (a bi-
guanide, sulfonylurea, thiazolidinedione,
or acarbose) at baseline were treated as a
separate cohort, with progression to use
of insulin as the study outcome.
Statistical analysis
All exposure groups were ﬁrst compared
on baseline variables. For each exposure
group, event rates were calculated. Next,
Cox proportional hazard models were
used to estimate unadjusted and adjusted
HRs.Fullyadjustedmodelswerereported
with all variables included in the model.
Covariates included the year that the
exposure therapy was initiated. They also
included a preidentiﬁed list of factors
known to be associated either positively
or negatively with diabetes. These in-
cluded sex, age, history of stroke, history
of myocardial infarction, and use of the
following drugs: ACE inhibitors, calcium
channelblockers,-blockers,thiazidedi-
uretics, loop diuretics, and corticoste-
roids (18). These drugs were analyzed as
baselinecovariatesandinsensitivityanal-
ysis as time-varying covariates. BMI and
smoking status were available only for a
portion of the population and were in-
cluded only in secondary analyses. The
presence of comorbidities was deter-
mined on the basis of identiﬁcation of
GPRD medical diagnostic codes in the
year before the ﬁrst ﬁbrate prescription.
Five secondary analyses were per-
formed: 1) comparison of bezaﬁbrate us-
ers versus users of each individual ﬁbrate;
2) stratiﬁcation by duration of therapy; 3)
stratiﬁcation of bezaﬁbrate users into ap-
proximate quartiles of average dosage
(200, 200–400, 400–600, and 600
mg/day) with use of the low-dose cate-
gory as a reference group; 4) restriction to
subjects with baseline BMI data and in-
corporation of BMI into multivariable
modeling; and 5) restriction to subject
with baseline smoking data and incorpo-
ration of smoking into multivariable
modeling.
RESULTS— Bezaﬁbrate was used far
more commonly (12,161 users) than any
other ﬁbrate (4,191 users). Of the other
ﬁbrateusers,1,465usedciproﬁbrate,502
used cloﬁbrate, 824 used fenoﬁbrate, and
1,400 used gemﬁbrozil. Baseline charac-
teristics of bezaﬁbrate users and other
ﬁbrate users were consistent with previ-
ously published research (Table 1) (18).
Because of the large sample size, most
baseline differences were statistically
signiﬁcant. However, few clinically sig-
niﬁcant differences were observed. Of
interest, however, the prevalence of re-
corded obesity was very similar (5% vs.
6%) between the two groups. However,
bezaﬁbrate users were more likely to be
female than other ﬁbrate users (48% vs.
40%).
Users of all other ﬁbrates were less
likely to have baseline diabetes than users
of bezaﬁbrate (relative risk 0.90 [95% CI
0.82–0.98] adjusted for year of the ﬁrst
ﬁbrate prescription). However, bezaﬁ-
brate users were less likely to have diabe-
tes before treatment initiation compared
with only one subgroup, the fenoﬁbrate
users (1.25 [1.08–1.42] adjusted for year
of ﬁrst ﬁbrate prescription).
Among bezaﬁbrate users, 272 new
cases of diabetes occurred, for an inci-
dence rate of 8.5 cases per 1,000 patient-
years (95% CI 7.5–9.5). Among users of
the other ﬁbrates, 131 new cases of dia-
betes occurred, for an incidence rate of
14.4 cases per 1,000 patient-years (12.1–
17.1).
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results are shown in Table 2. The unad-
justed HR for the comparison between
bezaﬁbrate and all other ﬁbrates was 0.58
(95%CI0.47–0.72).Adjustingforyearof
treatmentinitiationattenuatedtheassoci-
ation slightly, yielding a HR of 0.64
(0.52–0.79). No other variables modiﬁed
the point estimate by as much as 10%.
The fully adjusted HR for incident type 2
diabetes was 0.66 (0.53–0.81, P 
0.0001). Analyses were repeated with
stratiﬁcation by year of treatment initia-
tion, with no substantial change in the
results or evidence of heterogeneity of re-
sults by year (data not shown).
Table 2 also shows each individual ﬁ-
bratetreatedasadistinctreferencegroup.
Bezaﬁbrate had similar adjusted HRs
compared with those for ciproﬁbrate,
cloﬁbrate, and gemﬁbrozil (Table 2).
However, compared with fenoﬁbrate,
bezaﬁbrate was associated with a particu-
larly low hazard for diabetes (HR 0.41,
95% CI 0.29–0.58).
Table 3 shows the results of the dura-
tion-response analysis. The HR declined
monotonically as duration of therapy
increased.
No signiﬁcant relationship with aver-
age daily dose was seen (data not shown).
Neither restriction to individuals with
BMIdatanoradjustmentforBMIsubstan-
tially altered the results, although BMI of
25–30 kg/m
2 was associated with an HR
of 3.72 (95% CI 1.89–7.29) and BMI
30 kg/m
2 was associated with an HR of
6.98 (95% CI 3.51–13.88), with BMI
25 kg/m
2 as a reference group. The
same was true for restriction to individ-
uals with baseline smoking data and in-
clusion of that information in the
multivariable model (not shown).
In post hoc analysis, individuals with
baseline diabetes were classiﬁed as either
unmedicated (no record of use of antidi-
abetic medication) or receiving oral an-
tidiabetic medication. The distribution of
baselinecharacteristicsbetweenexposure
groups was generally similar to that in the
original cohort (data not shown).
Table4showsHRscalculatedforpro-
gression from unmedicated diabetes at
the time of ﬁbrate initiation to use of any
antidiabetic medication (including insu-
lin), as well as HRs for progression from
useofanoralantidiabeticdrugatbaseline
to insulin use. Bezaﬁbrate was associated
with a lower hazard of progression to an-
tidiabetic medication use compared with
ﬁbrates (HR 0.54, 95% CI 0.38–0.76).
The HRs were not substantially altered by
multivariable adjustment.
The analysis was repeated with indi-
viduals who used oral antidiabetic medi-
cations at baseline, with progression to
insulin therapy as the outcome. Bezaﬁ-
bratewasassociatedwithanonsigniﬁcant
trend toward a lower hazard of progres-
siontoinsulintherapy(adjustedHR0.78,
95% CI 0.55–1.10).
No signiﬁcant differences in HRs
were observed for sex. Data on ethnicity
were not available for this study.
CONCLUSIONS — This study pro-
vides strong evidence that bezaﬁbrate has
antidiabetic properties, supporting both
Table 1—Baseline characteristics and number of events in exposure groups





Mean duration of use (years) 2.6 2.2 0.0001
Mode year of treatment initiation 1993 1994 0.0001
Age (years)
50 20 22 0.0112
50–59 33 33 0.9840
60–69 37 33 0.0001
69 10 12 0.0008
Male sex 52 60 0.0001
History of myocardial infarction 1 1 0.7529
History of stroke 0 0 0.9676
History of ACE inhibitor/angiotensin receptor
blocker use
5 6 0.0018
History of calcium channel blocker use 24 22 0.1756
History of -blocker use 16 17 0.2382
History of loop diuretic use 5 5 0.2178
History of thiazide diuretic use 9 8 0.2883
History of corticosteroid use 3 3 0.6388
Never smoker 19 21 0.5114
Ever smoker 39 41 0.5114
Not reported 42 38 0.0001
BMI
25 kg/m
2 9 8 0.0449
25–29.9 kg/m
2 13 13 0.6363
29.9 kg/m
2 5 6 0.0035
Not reported 73 72 0.0523
Number of cases of incident diabetes 272 131
Cases/1,000 person-years (95% CI) 8.5 (7.5–9.5) 14.4 (12.1–17.1) 0.001
Data are % unless indicated otherwise. Individuals with baseline diabetes were excluded. History of cardio-
vascular events and drug use refer to history in the year before cohort entry. P values were generated using
	
2 and t tests.
Table 2—Prespeciﬁed secondary analyses consisting of HRs for exposure to bezaﬁbrate
Reference group
HRs (95% CI) for incident type 2 diabetes in
individuals exposed to bezaﬁbrate
Unadjusted Fully adjusted
All ﬁbrate users 0.58 (0.47–0.72) 0.66 (0.53–0.81)
Ciproﬁbrate users 0.53 (0.39–0.73) 0.72 (0.52–0.99)
Cloﬁbrate users 1.17 (0.63–2.14) 0.78 (0.54–1.14)
Gemﬁbrozil users 0.30 (0.21–0.42) 0.84 (0.46–1.55)
Fenoﬁbrate users 0.81 (0.57–1.19) 0.41 (0.29–0.58)
Fully adjusted HRs are adjusted for year of treatment initiation, age, sex, history of congestive heart failure,
historyofmyocardialinfarction,andhistoryofuseofthiazidediuretics,loopdiuretics,-blockers,calcium-
channel blockers, ACE inhibitors, angiotensin receptor blockers, or steroids.
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suggesting that bezaﬁbrate can prevent or
delaytheonsetoftype2diabetes(5–7).It
further indicates that this effect is unique
to bezaﬁbrate among the ﬁbrates. These
ﬁndings have important implications for
research. Our ﬁndings are bolstered by
the similarity of subjects in exposure
groups on clinically relevant character-
istics, the fact that the ﬁnding of a pro-
tective effect is of a clinically relevant
magnitude, statistically signiﬁcant, and
robust to sensitivity analyses including




fenoﬁbrate was more likely to be pre-
scribed to individuals with a high risk for
diabetes or unrecorded diabetes, creating
a falsely elevated hazard for development
of diabetes during fenoﬁbrate treatment
compared with bezaﬁbrate treatment. It
was hence useful to do a post hoc analysis
conﬁned to individuals who already had
diabetes. In this post hoc analysis, bezaﬁ-
brate also appeared to have antidiabetic
properties.
Taken together, these ﬁndings sup-
port and complement previous observa-
tions. Post hoc analyses of the Bezaﬁbrate
Infarction Prevention (BIP) Study have
suggestedthatbezaﬁbratemayreducethe
hazard for incident diabetes, with point
estimates for the HR of 0.59 and 0.70
(5,6). The fully adjusted point estimate
from our study (0.66, 95% CI 0.3–0.81)
is very consistent with those earlier re-
sults. These additional results are impor-
tant because they conﬁrm a post hoc
analysis in a new study with this as a pre-
speciﬁed hypothesis, they generalize the
results to a broader population than the
original post hoc analysis did, and they
provide considerably more precise point
estimates.
Another publication from the BIP
showed that bezaﬁbrate attenuated pro-
gression of the homeostasis model assess-
ment of insulin resistance marker for
insulin resistance in all patients, suggest-
ing that bezaﬁbrate might also slow pro-
gression of diabetes (7). Our results were
consistent with that hypothesis as well,
both for progression from diagnosis to
any use of antidiabetic drugs (HR 0.54,
95% CI 0.38–0.76) and for progression
from use of oral antidiabetics to insulin
(0.78, 0.55–1.10). The ﬁnding for pro-
gressiontoinsulinwasatrendbutwasnot
statistically signiﬁcant. In addition, the
ﬁndings on diabetes progression should
be noted to be post hoc and are not ad-
justed for multiple comparisons.
Themajorlimitationofthisstudywas
the potential for unadjusted confound-
ing,aprobleminanyobservationalstudy.
Despite the similar indications for the
ﬁbrates, the drugs are clearly not identi-
cally prescribed. Most strikingly, bezaﬁ-
brate was by far the most commonly used
ﬁbrate in the U.K. and had the highest
proportion of female users. Of most
concern, rates of baseline diabetes dif-
fered by exposure group. Adjusting for
these baseline differences did not
change our results. Further, it is reas-
suring that bezaﬁbrate still appeared to
be protective even when compared with
ciproﬁbrate, cloﬁbrate, or gemﬁbrozil
(which were not preferentially pre-
scribed to diabetic subjects compared
with bezaﬁbrate). It is especially reas-
suring that a post hoc analysis of diabe-
tesprogressionthatcouldnothavebeen
confounded by preferential prescribing
to diabetic subjects still showed a pro-
tective effect from bezaﬁbrate. We in
turn note that this post hoc analysis was
not part of the original study design,
was subject to false-positive results due
to multiple comparisons, and used
rough proxies for diabetes progression
(progression to oral or insulin therapy).
No observational study can completely
exclude the possibility of confounding
by indication, and the results of this
study need to be conﬁrmed in a subse-
quent randomized study. Another po-
tential limitation of this study is the
likelihood that some incident cases of
diabetes were not captured by the data-
base; however, such misclassiﬁcation
would most likely be nondifferential
and would bias any ﬁnding toward the
null.
In summary, this study strongly sup-
portstheideathatbezaﬁbratecanprevent
type 2 diabetes, conﬁrming a post hoc
analysis in a prior study. The effect size
estimates from this study are comparable
to those reported for other studies assess-
ingtheuseofthiazolidinedionesandmet-
formin to prevent diabetes (19). Given
concerns about cardiovascular risk with
existing oral antidiabetic agents (20,21),
bezaﬁbrate may offer a unique opportu-
nity to treat or prevent diabetes while
maintaining a favorable cardiovascular
risk-beneﬁt proﬁle. However, it would
not be appropriate to establish a new in-
dication without randomized controlled
trial data to conﬁrm these ﬁndings, simi-
lar to those recently conducted to study
the antidiabetic properties of colesevelam
(22). In light of the increasing population
riskofdiabetes,atrialthatcouldestablish
the effectiveness of an inexpensive and
Table 3—HRs stratiﬁed by years of cumulative use
Reference group
Fully adjusted HRs (95% CI) stratiﬁed by years of
cumulative exposure
Year 1 Years 2–3 Years 4–5
All ﬁbrate users 0.74 (0.52–1.05) 0.62 (0.44–0.89) 0.57 (0.35–0.93)
Fully adjusted HRs are adjusted for year of treatment initiation, age, sex, history of congestive heart failure,
historyofmyocardialinfarction,andhistoryofuseofthiazidediuretics,loopdiuretics,-blockers,calcium-
channel blockers, ACE inhibitors, angiotensin receptor blockers, or steroids.
Table 4—Cox proportional hazard models for ad hoc analysis
Reference group
Fully adjusted HRs (95% CI)
For progression from unmedicated
baseline diabetes to use of oral
antidiabetic therapy
For progression from baseline use
of oral antidiabetic therapy to use
of insulin
All ﬁbrate users 0.54 (0.38–0.76) 0.78 (0.55–1.10)
Ciproﬁbrate users 0.44 (0.28–0.69) 0.78 (0.50–1.22)
Fenoﬁbrate users 0.57 (0.32–1.02) 0.86 (0.52–1.42)
Gemﬁbrozil users 0.74 (0.38–1.43) 0.57 (0.31–1.05)
All models treat bezaﬁbrate as the exposure; reference group varies by row. Cloﬁbrate was not used alone as
a reference group because of an insufﬁcient number of observations in the cloﬁbrate group to support
multivariable modeling. Fully adjusted models are adjusted for year of treatment initiation, age, sex, history
of congestive heart failure, history of stroke, and history of drug use (ACE/angiotensin receptor blocker,
calcium channel blocker, loop diuretic, thiazide diuretic, -blocker, or steroid).
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ment should be strongly considered for
prioritization by funding agencies.
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